17 reports

Global Addiction Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Addiction Disorder
  • Mental Health
  • United States
  • World
  • Forecast

Europe Addiction Disorder Epidemiology and Patient Flow Analysis - 2017 ##.

  • Addiction Disorder
  • Europe
  • France
  • Germany
  • Forecast

Global Addiction Disorders Epidemiology and Patient Flow Analysis - 2016 ##.

  • Addiction Disorder
  • Mental Health
  • United States
  • World
  • Forecast

Specialty treatment services provide treatment relating to eating disorders and addiction.

  • Addiction Disorder
  • Specialty Hospital
  • World
  • Acadia Healthcare Company, Inc.
  • Universal Health Services, Inc.
  • IMV INC
  • AUG 01, 2017: AMYGDALA NEUROSCIENCES INITIATES PHASE 1B CLINICAL STUDY OF ANS-6637, THE FIRST-IN-CLASS SELECTIVE ALDH2 INHIBITOR IN DEVELOPMENT AS A TREATMENT FOR SUBSTANCE USE DISORDER

Protagenic Therapeutics is developing PT-## (TCAP-##) for the treatment of depression, anxiety, mood disorders, opioid addiction and other neurodegenerative disorders including stress-related disorders.

  • Addiction Disorder
  • Therapy
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • Clinical Trial profile. 320 Trial Title
  • Target

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Clinical Trial
  • Opioid
  • World
  • Alkermes plc

Camurus' products have therapeutic applications in the areas of cancer, endocrine disorders, pain, oral mucositis, metabolic disease, growth hormone disorders and drug addiction.

  • Addiction Disorder
  • Opioid
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd
  • 18-MC - Drug Profile
  • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile

Omeros believes that PDE## inhibitors could be effective therapeutics for the treatment of addiction and compulsive disorders as well as movement disorders.

  • Addiction Disorder
  • Pharmaceutical
  • United States
  • World
  • Product Initiative

" Opioid addiction is one of the worst public health crises in our nation' s history.

  • Addiction Disorder
  • Opioid
  • United States
  • Product Initiative
  • Addex Therapeutics Ltd

BETA. )-##-(##, ##-BENZODIOXOL-##-YL)-##-HYDROXY-##-(##-PROPYNYL)-ESTRA-##, ##-DIEN-##-ONE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER".

  • Addiction Disorder
  • Antiseptics
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • Target
  • Clinical Trial profile. 79 Trial Title

ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* ALCOHOL ADDICTION THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, 2017* Company Name Ph

  • Addiction Disorder
  • Antiseptics
  • United States
  • World
  • Alkermes plc
  • MAJOR MARKETS CONTINUED
  • MAJOR MARKETS CONTINUED

The more common types include anxiety disorders, mood disorders, psychotic disorders, eating disorders, impulse control and addiction disorders and personality disorders.

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Specialty Hospital
  • United States
  • PRODUCTS & SERVICES CONTINUED

Mental illness and substance abuse disorder According to the National Alliance on Mental Illness (NAMI), ##. ## million adults have co-occurring mental health and addiction disorders.

  • Addiction Disorder
  • Health Care Provider
  • Mental Health
  • United States
  • Forecast
  • Target
  • Clinical Trial profile. 318 Trial Title

Risperidone for Bipolar Disorder with Comorbid Substance Use Disorder Divalproex ER vs.

  • Addiction Disorder
  • Clinical Trial
  • Pharmaceutical
  • United States
  • World
  • AUG 01, 2017: AMYGDALA NEUROSCIENCES INITIATES PHASE 1B CLINICAL STUDY OF ANS-6637, THE FIRST-IN-CLASS SELECTIVE ALDH2 INHIBITOR IN DEVELOPMENT AS A TREATMENT FOR SUBSTANCE USE DISORDER
  • OCT 18, 2017: ALTASCIENCES CONDUCTS ALCOHOL DRUG-DRUG INTERACTION STUDY FOR AMYGDALA NEUROSCIENCES

HAS BEEN AMENDED TO INCLUDE ADDICTION AND COMPULSIVE DISORDERS IN THE FIELD OF USE.

  • Addiction Disorder
  • Therapy
  • United States
  • Product Initiative
  • MediciNova, Inc.

Johnson is one of the world' s most renown and sought after addiction experts.

  • Addiction Disorder
  • Antiseptics
  • United States
  • Product Initiative
  • MediciNova, Inc.
  • NICOTINE ADDICTION - PIPELINE BY CV SCIENCES INC

The company develops medications to treat addiction and related disorders.

  • Addiction Disorder
  • Opioid
  • Company
  • Product Initiative
  • Omeros Corporation